Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Lydon Nicholas					2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ]										tionship of Reportin all applicable) Director		10% Owi		wner
	(Fir JEPRINT M EY STREE	MEDICINES CO	Middle)		10/0	3. Date of Earliest Transaction (Month/Day/Year) 10/01/2020									Officer (give title below)		Other (s below)		
	IDGE MA		2139		4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	fividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City)	(5)		Zip)																
1. Title of Security (Instr. 3) 2. Tra			2. Transaction		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		d (A) or	or 5. Am 4 and 5) Secur Benef		unt of ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Price	Trans		action(s) 3 and 4)			(moa. 4)			
Common Stock				10/01/2020				S <sup>(1)</sup>		3,896	D	\$93.6	58 <sup>(2)</sup>	43,344			D		
Common Stock 1				10/01/2	/2020				S <sup>(1)</sup>		4,530	D	\$92.8	8(3) 38,		8,814		D	
Common Stock			10/01/2020				S <sup>(1)</sup>		1,389	D	\$92.0	J6 <sup>(4)</sup> 3'		37,425		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ive Conversion Date y or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration D		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date		Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.36 to \$94.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$92.39 to \$93.35 per share.
- 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.89 to \$92.24 per share.

/s/ Christopher Frankenfield Attorney-in-Fact

10/05/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.